SPEED: Patient Actor Training to Improve HIV Services for Adolescents in Kenya

Sponsor
University of Washington (Other)
Overall Status
Completed
CT.gov ID
NCT02928900
Collaborator
University of Nairobi (Other)
7,450
6
2
54.1
1241.7
22.9

Study Details

Study Description

Brief Summary

The goal of this study is to develop and evaluate a clinical training intervention utilizing standardized patient actors to improve communication and interpersonal skills of health care workers who serve HIV-infected adolescents and youth in Kenya, resulting in increased engagement in HIV care. The effect of the intervention on retention in care will be evaluated in a stepped-wedge randomized controlled trial at 24 HIV care and treatment facilities.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Clinician training intervention
N/A

Detailed Description

Adolescents and youth have the highest HIV incidence rates compared to any other age strata. Inadequate provision of accessible and acceptable HIV testing, counseling, and treatment services has been cited as a barrier to uptake of and retention in HIV care in this population.

The "SPEED" study aims to develop and evaluate a clinical training intervention utilizing Standardized Patient (SP) actors to improve communication and interpersonal skills of health care workers (HCWs) who work with adolescents and youth (ages 10-24), resulting in increased engagement in HIV care in Kenya. This intervention includes a series of role plays between HCW participants and professional Kenyan actors, followed by feedback and debriefing sessions. The hypothesis is that SP encounters will increase HCW confidence and capacity to facilitate HIV status disclosure and provide supportive interactions with HIV-infected youth, which will in turn increase uptake and improve retention in HIV services among adolescents and youth.

The pilot phase (Aim 1) will consist of developing patient case scripts specific to adolescent HIV-related care and counseling needs and establishing HCW competency scores. To evaluate the intervention, a cluster randomized controlled stepped-wedge trial will be conducted in 24 HIV care and treatment facilities to assess the impact of SP encounters on the proportion of adolescents and youth patients retained in care at HIV treatment facilities in Kenya (Aim 2). Finally, the cost effectiveness and cost utility of the SP intervention will be determined (Aim 3). The estimated study duration is five years.

The primary outcomes from Aim 1 are final scripts and pass/fail scores for use in SP encounters. The primary outcome for the randomized controlled trial (RCT) (Aim 2) is retention in care among HIV-positive adolescents and youth, based on electronic medical records data. Secondary outcomes will include satisfaction (patients and HCWs), HCW competency in youth- friendly counseling, antiretroviral therapy adherence, and viral suppression. For the cost effectiveness and cost utility analyses (Aim 3), the cost per additional HIV-infected adolescent/youth retained in care and the cost per additional life year saved and disability-adjusted life averted will be estimated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
7450 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Simulated Patient Encounters to Promote Early Detection and Engagement in HIV Care for Adolescents
Actual Study Start Date :
Sep 26, 2016
Actual Primary Completion Date :
Nov 2, 2020
Actual Study Completion Date :
Mar 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention period

In this stepped-wedge trial design, the experimental arm refers to the time period when the study sites receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care providers who serve HIV-positive adolescents and youth.

Behavioral: Clinician training intervention
This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.

No Intervention: Control period

In this stepped-wedge trial design, the no intervention arm refers to the time period before the study sites receive the clinician training intervention, during which standard of care is provided.

Outcome Measures

Primary Outcome Measures

  1. Retention in HIV care [Up to four years after baseline]

    The primary outcome is change in retention in HIV care between the intervention and control periods, where retention is defined as return for first follow-up visit within 3 months among newly enrolled adolescent clients OR follow-up visit after 're-engagement visit' (after lost-to-follow-up for >90 days since last visit, with no record of death or transfer).

Secondary Outcome Measures

  1. Proportion of HCWs with pass/fail scores [Up to one month after last day of training]

    The proportion of HCW participants who achieved competency upon completion of the training.

  2. Numeric scores from SP actors [Up to one week after last day of training]

    All SP actors will complete a check-list to provide non-technical feedback to each HCW participant. Scores will be used to compute the overall pass/fail score at completion of the training.

  3. Health care worker competency [Baseline and every nine months for up to four years]

    This outcome is measured as change in mean competency score between intervention and control periods using a structured survey.

  4. Health care workers' satisfaction with skills [Baseline and every nine months for up to four years]

    This outcome is measured as change in mean satisfaction scores between intervention (post-training) and control periods (pre-training), using a structured survey. These surveys will be conducted at baseline, and every nine months at the end of the training in each wave. Exit interviews among trained participants will be conducted about one year after each training wave for up to four waves to complement the quantitative results.

  5. Adolescent patients' satisfaction with care [Baseline and every nine months for up to four years]

    This outcome is defined as mean change in satisfaction score between intervention and control periods, using a structured survey.

  6. Cost per additional HIV-infected adolescent retained in care [End of study, up to four years]

    This outcome measure will be computed based on a mathematical model of total direct and indirect costs using a combination of primary data collection (surveys), program data, and published literature. The denominator will be the number of adolescents retained in care.

  7. Cost-utility of the intervention [End of study, up to four years]

    This outcome measure will be computed using a mathematical model of cost per life year saved and disability-adjusted life year (DALY), where cost data will come from primary data, program records, and literature, and denominator data will come from the most relevant models of DALYs for adolescents.

  8. Retention in HIV care (secondary) [Baseline and every nine months for up to four years]

    A secondary measure of retention in HIV care is return for any follow-up visit within 3 months (90 days) among currently enrolled HIV-positive adolescent patients

Other Outcome Measures

  1. antiretroviral (ART) adherence in HIV-positive adolescents [Baseline and every nine months for up to four years]

    This measure is defined as change in the proportion of visits with ART refills within 1 week of scheduled visit between intervention and control periods using available electronic medical record (EMR) data.

  2. Viral load in HIV-positive adolescents [Baseline and every nine months for up to four years]

    This measure is defined as change in viral load between intervention and control periods using available EMR data.

  3. Linkage to adolescent friendly services in HIV-positive adolescents [Baseline and every nine months for up to four years]

    This measure is defined as change in the proportion of visits with referrals to affiliated services (e.g. family planning) between intervention and control periods using available EMR data.

  4. AIDS defining illness in HIV-positive adolescents [Baseline and every nine months for up to four years]

    This measure is defined as change in the proportion of visits with any AIDS defining illness between intervention and control periods using available EMR data.

  5. Mortality in HIV-positive adolescents [Baseline and every nine months for up to four years]

    This measure is defined as change in the proportion of deaths between intervention and control periods using available EMR data.

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes

Inclusion Criteria: Listed by population

Facilities:
  • HIV care and treatment facilities in Kenya with ≥40 adolescents currently in HIV care

  • EMR data systems

  • No concurrent adolescent interventions

Adolescent patient records:
  • Records of adolescents and youth ages 10-24

  • Enrollment in HIV care and treatment at one of the study facilities

Adolescent satisfaction surveys:
  • Patients ages 10-24 seeking counseling or treatment services at trial site who are HIV-infected

  • Willing and able to provide informed consent or assent based on age and presence of a caregiver.

  • Reside in Kenya

Health care workers:
  • 18 years of age

  • Employed at trial site in clinical care for at least three months and/or have a 1 year contract (i.e. not temporary staff)

  • Provide clinical services to adolescents

  • Reside in Kenya

Exclusion Criteria:
Facilities:
  • If inclusion criteria are not met

  • If anything would prevent the complete conduct of the training intervention at that site and/or the collection of outcome measures

Adolescents and health care worker surveys:

• If an individual has conditions that would place them at increased risk or preclude the individual's full compliance with or completion of the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 HIV care facility 6 Homa Bay Kenya
2 HIV care facility 3 Kiambu Kenya
3 HIV care facility 4 Kiambu Kenya
4 HIV care facility 5 Kisumu Kenya
5 HIV care facility 1 Nairobi Kenya
6 HIV care facility 2 Nairobi Kenya

Sponsors and Collaborators

  • University of Washington
  • University of Nairobi

Investigators

  • Principal Investigator: Pamela Kohler, PhD, MPH, RN, University of Washington
  • Study Director: Dalton Wamalwa, MMed, MPH, University of Nairobi

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Pamela Kohler, Assistant Professor, Global Health and Nursing, University of Washington
ClinicalTrials.gov Identifier:
NCT02928900
Other Study ID Numbers:
  • STUDY00002035
First Posted:
Oct 10, 2016
Last Update Posted:
Jun 10, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Keywords provided by Pamela Kohler, Assistant Professor, Global Health and Nursing, University of Washington
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 10, 2021